Health Condition 1: J309- Allergic rhinitis, unspecified
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Clinically diagnosed cases of allergic rhinitis according to ARIA guidelines Participants with mild to moderate symptoms of allergic rhinitis. Willing to provide written informed consent. Participants who have not taken anti-allergic medications for at least 2 weeks prior to enrollment.
Exclusion criteria
Exclusion criteria: Participants with nasal polyps, deviated nasal septum, chronic sinusitis, asthma, or other systemic illnesses. Participants already under long-term antihistamines, corticosteroids, or immunotherapy. Pregnant or lactating women. Participants with any life-threatening illnesses (e.g., malignancies, uncontrolled systemic diseases) or classified as part of a vulnerable population. Participants with psychiatric disorders or cognitive impairment affecting their ability to give consent or adhere to protocol. Participants already participating in another clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the change in allergic rhinitis symptoms using the Total Nasal Symptom Score (TNSS) in both groups.Timepoint: 6 months for patient recruitment and intervention 6 months for follow ups 2 months for data analysis and interpretation 2 months of report writing. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the improvement in quality of life using the Mini Rhinoconjunctivitis Quality of Life Questionnaire. Evaluate changes in serum IgE levels pre- and post treatment. Timepoint: 6 months for patient recruitment and intervention 6 months for follow ups 2 months for data analysis and interpretation 2 months of report writing. | — |
Countries
India
Contacts
Bakson Homoeopathic Medical College and Hospital